肠道菌群、血清HMGB1与急性呼吸窘迫综合征患儿免疫功能、病情程度的关系及预后预警作用OA
Relationship of intestinal flora and serum HMGB1 with immune function and disease severity in children with acute respiratory distress syndrome,as well as their prognostic warning effect
目的 探究肠道菌群、血清高迁移率族蛋白1(HMGB1)与急性呼吸窘迫综合征(ARDS)患儿病情程度、免疫功能的相关性,并分析其对预后的预警作用.方法 选取2022年10月—2023年10月收治的134例ARDS患儿为ARDS组,另选取同期70例健康体检儿童为对照组,比较两组肠道菌群、血清HMGB1水平,比较不同病情程度ARDS患儿肠道菌群、血清HMGB1、免疫功能指标(CD3+、CD4+、CD4+/CD8+、IgA、IgG、IgM);分析ARDS患儿肠道菌群、血清HMGB1与病情程度、免疫功能指标的相关性;分析肠道菌群、血清HMGB1对ARDS患儿预后的评估价值,采用RR相对危险度分析其预警作用.结果 ARDS组大肠杆菌数量、血清HMGB1水平高于对照组,乳酸杆菌、双歧杆菌、真杆菌、消化球菌数量均低于对照组(P<0.05).重度亚组ARDS患儿大肠杆菌数量、血清HMGB1水平高于中度亚组、轻度亚组,乳酸杆菌、双歧杆菌、真杆菌、消化球菌数量以及免疫功能指标均低于中度亚组、轻度亚组(P<0.05).ARDS患儿大肠杆菌、血清HMGB1与病情程度呈正相关,与各免疫功能指标均呈负相关(P<0.05);乳酸杆菌、双歧杆菌、真杆菌、消化球菌与病情程度呈负相关,与各免疫功能指标均呈正相关(P<0.05).上述肠道菌群与血清HMGB1联合评估ARDS患儿预后的曲线下面积为0.928(95%CI:0.871,0.966),敏感度为80.77%、特异度为87.96%(P<0.05).大肠杆菌、乳酸杆菌、双歧杆菌、真杆菌、消化球菌、血清HMGB1高水平患儿预后不良风险分别是低水平患儿的4.643、0.212、0.196、0.156、0.176、5.552倍(P<0.05).结论 ARDS患儿肠道菌群及血清HMGB1异常,与ARDS病情严重程度、免疫功能状态关系密切,二者联合对ARDS预后有一定评估价值,有利于判断患儿预后不良风险.
Objective To investigate the correlation of intestinal flora and serum high mobility group box 1 protein(HMGB1)with the disease severity and immune function of pediatric patients with acute respiratory distress syndrome(ARDS),and to analyze its prognostic warning effect.Methods A total of 134 children with ARDS admitted from October 2022 to October 2023 were selected as the ARDS group,and 70 healthy children undergoing physical examination during the same period were selected as the control group.The levels of intestinal flora and serum HMGB1 were compared between the two groups.The intestinal flora,serum HMGB1 and immune function indexes(CD3+,CD4+,CD4+/CD8+,IgA,IgG,IgM)of children with ARDS of different severity were compared.The correlation between intestinal flora,serum HMGB1 and disease severity,immune function indicators in children with ARDS was analyzed.The prognostic value of intestinal flora and serum HMGB1 in children with ARDS was analyzed,and the early warning effect was analyzed by relative risk(RR).Results The number of Escherichia coli and serum HMGB1 level in ARDS group were higher than those in control group,while the number of Lactobacillus,Bifidobacterium,Eubacterium and Peptococcus were lower than those in control group(P<0.05).The number of Escherichia coli and serum HMGB1 level in ARDS children in severe subgroup were higher than those in moderate subgroup and mild subgroup,while the number of Lactobacillus,Bifidobacterium,Eubacterium,Digestive cocci and immune function indexes were lower than those in moderate subgroup and mild subgroup(P<0.05).The levels of Escherichia coli and serum HMGB1 in children with ARDS were positively correlated with the severity of the disease,and negatively correlated with the immune function indexes(P<0.05).Lactobacillus,Bifidobacterium,Eubacterium and Peptococci were negatively correlated with the severity of the disease,and positively correlated with each immune function index(P<0.05).The area under the receiver operating characteristic(ROC)curve of the above intestinal flora combined with serum HMGB1 in evaluating the prognosis of children with ARDS was 0.928(95%CI:0.871,0.966),with the sensitivity of 80.77%,and the specificity of 87.96%(P<0.05).The risk of poor prognosis in children with high levels of Escherichia coli,Lactobacillus,Bifidobacterium,Eubacterium,Digestive cocci,and serum HMGB1 was 4.643,0.212,0.196,0.156,0.176,and 5.552 times that of children with low levels(P<0.05).Conclusion The abnormalities of intestinal flora and serum HMGB1 in children with ARDS are closely related to the severity of ARDS and the status of immune function.The combination of the two has certain evaluation value for the prognosis of ARDS,which is conducive to identifying the risk of poor prognosis in children.
李佳瑩;李国庆;卢斌
济南市妇幼保健院儿童保健科,济南 250000济南市第三人民医院儿科,济南 250000济南市妇幼保健院儿童保健科,济南 250000
急性呼吸窘迫综合征儿童肠道菌群高迁移率族蛋白1免疫功能预后
acute respiratory distress syndromechildintestinal florahigh mobility group box 1 proteinimmune functionprognosis
《临床误诊误治》 2026 (9)
47-53,7
2021年度山东省医药卫生科技发展计划项目(202103030550)济南市卫生健康委员会2021年科技计划项目(2021-2-49)
评论